Company: GANX
Filing Date: 2025-05-28
Form Type: S-3
Source: 0001104659-25-053619
Chunk: 42

Company: Gain Therapeutics, Inc.
Filing Date: 2025-05-28
Form: S-3
Chunk 42
---
 10-K).                                           | ​ | ​ | ​        | ​ | ​ | ​          | ​ | ​ |                         ​ | ​ | ​ | ​         | ​ |
| ​ |       25.1*** | ​ | ​ | Statement of Eligibility on Form T-1 under the Trust Indenture Act of 1939, as amended, of the Trustee for the Senior Debt Indenture       | ​ | ​ | ​        | ​ | ​ | ​          | ​ | ​ |                         ​ | ​ | ​ | ​         | ​ |
| ​ |       25.2*** | ​ | ​ | Statement of Eligibility on Form T-1 under the Trust Indenture Act of 1939, as amended, of the Trustee for the Subordinated Debt Indenture | ​ | ​ | ​        | ​ | ​ | ​          | ​ | ​ |                         ​ | ​ | ​ | ​         | ​ |
| ​ |          107* | ​ | ​ | Filing Fee Table                                                                                                                           | ​ | ​ | ​        | ​ | ​ | ​          | ​ | ​ |                         ​ | ​ | ​ | ​         | ​ |

* Filed Herewith ** To be filed, if applicable, by amendment or by a report filed under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, and incorporated herein by reference. *** To be filed pursuant to Section 305(b)(2) of the Trust Indenture Act of 1939, as amended.

II-2

TABLE OF CONTENTS

## Item 17.   Undertakings
(a) The undersigned Registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933,

(ii) to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may